#METABOLOMICS WORKBENCH michaelsa93_20170720_090923_mwtab.txt DATATRACK_ID:1163 STUDY_ID:ST000808 ANALYSIS_ID:AN001281
VERSION             	1
CREATED_ON             	July 24, 2017, 12:00 pm
#PROJECT
PR:PROJECT_TITLE                 	Establishing the Validity of a Mid-Pregnancy Serum Archive for Novel Studies of
PR:PROJECT_TITLE                 	Perinatal Outcomes
PR:PROJECT_SUMMARY               	This study aims to establish a set of test samples that will be used to validate
PR:PROJECT_SUMMARY               	the utility of the banked biospecimens, which will serve as critical preliminary
PR:PROJECT_SUMMARY               	data for future NIH grant proposals. Specifically, for the current proposal we
PR:PROJECT_SUMMARY               	aim to: 1) Collect test samples. We will design a sample collection protocol
PR:PROJECT_SUMMARY               	that mimics “ideal” and “worst-case” sample handling conditions and
PR:PROJECT_SUMMARY               	collect and store the samples for future testing. 2) Establish the validity of
PR:PROJECT_SUMMARY               	the samples for measuring lipid mediators and global metabolomics. We will use
PR:PROJECT_SUMMARY               	the test samples to accomplish this Aim. The test samples were stored in small
PR:PROJECT_SUMMARY               	aliquots for this proposal as well as future validation studies. Targeted
PR:PROJECT_SUMMARY               	metabolomic analyses of oxylipins, endocannabinoids, ceramides, and bile acids
PR:PROJECT_SUMMARY               	on human serum samples were performed by the Newman lab. Analysis of primary
PR:PROJECT_SUMMARY               	metabolism and complex lipids was performed by the Fiehn lab.
PR:INSTITUTE                     	Stanford University
PR:DEPARTMENT                    	Pediatrics - Neonatology
PR:LAST_NAME                     	Carmichael
PR:FIRST_NAME                    	Suzan
PR:ADDRESS                       	450 Serra Mall, Stanford, CA 94305
PR:EMAIL                         	scarmichael@stanford.edu
PR:PHONE                         	(650) 736-0735
#STUDY
ST:STUDY_TITLE                   	Establishing the Validity of a Mid-Pregnancy Serum Archive for Novel Studies of
ST:STUDY_TITLE                   	Perinatal Outcomes (part VI)
ST:STUDY_TYPE                    	Retrospective cohort study
ST:STUDY_SUMMARY                 	This study aims to establish a set of test samples that will be used to validate
ST:STUDY_SUMMARY                 	the utility of the banked biospecimens, which will serve as critical preliminary
ST:STUDY_SUMMARY                 	data for future NIH grant proposals. Specifically, for the current proposal we
ST:STUDY_SUMMARY                 	aim to: 1) Collect test samples. We will design a sample collection protocol
ST:STUDY_SUMMARY                 	that mimics “ideal” and “worst-case” sample handling conditions and
ST:STUDY_SUMMARY                 	collect and store the samples for future testing. 2) Establish the validity of
ST:STUDY_SUMMARY                 	the samples for measuring lipid mediators and global metabolomics. We will use
ST:STUDY_SUMMARY                 	the test samples to accomplish this Aim. The test samples were stored in small
ST:STUDY_SUMMARY                 	aliquots for this proposal as well as future validation studies. Targeted
ST:STUDY_SUMMARY                 	metabolomic analyses of oxylipins, endocannabinoids, ceramides, and bile acids
ST:STUDY_SUMMARY                 	on human serum samples were performed by the Newman lab. Analysis of primary
ST:STUDY_SUMMARY                 	metabolism and complex lipids was performed by the Fiehn lab.
ST:INSTITUTE                     	U.S.D.A. Western Human Nutrition Research Center, University of California,
ST:INSTITUTE                     	Davis
ST:DEPARTMENT                    	Nutrition
ST:LABORATORY                    	Newman Lab
ST:LAST_NAME                     	Newman
ST:FIRST_NAME                    	John
ST:ADDRESS                       	430 W. Health Sciences Dr., Davis, CA 95616
ST:EMAIL                         	john.newman@ars.usda.gov
ST:PHONE                         	+1-530-752-1009
#SUBJECT
SU:SUBJECT_TYPE                  	Human
SU:SUBJECT_SPECIES               	Homo sapiens
SU:TAXONOMY_ID                   	9606
SU:GENDER                        	Females
SU:SUBJECT_COMMENTS              	Obese pregnant femals
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data
SUBJECT_SAMPLE_FACTORS           	PT18_biob_UCD4	CRS_01	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT08_biob_UCD4	CRS_02	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT20_biob_UCD4	CRS_03	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT09_biob_UCD2	CRS_04	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT11_biob_UCD4	CRS_05	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT16_ideal_UCD2	CRS_06	Treatment:Ideal	
SUBJECT_SAMPLE_FACTORS           	PT08_biob_UCD2	CRS_07	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT12_biob_UCD2	CRS_08	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT12_biob_UCD4	CRS_09	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT02_ideal_UCD2	CRS_10	Treatment:Ideal	
SUBJECT_SAMPLE_FACTORS           	PT10_biob_UCD2	CRS_11	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT15_biob_UCD4	CRS_12	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT19_biob_UCD2	CRS_13	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT03_biob_UCD4	CRS_14	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT18_ideal_UCD2	CRS_15	Treatment:Ideal	
SUBJECT_SAMPLE_FACTORS           	PT07_ideal_UCD2	CRS_16	Treatment:Ideal	
SUBJECT_SAMPLE_FACTORS           	PT11_biob_UCD2	CRS_17	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT13_ideal_UCD2	CRS_18	Treatment:Ideal	
SUBJECT_SAMPLE_FACTORS           	PT20_biob_UCD2	CRS_19	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT17_biob_UCD4	CRS_20	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT04_biob_UCD2	CRS_21	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT20_ideal_UCD2	CRS_22	Treatment:Ideal	
SUBJECT_SAMPLE_FACTORS           	PT01_biob_UCD4	CRS_23	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT17_biob_UCD2	CRS_24	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT06_ideal_UCD2	CRS_25	Treatment:Ideal	
SUBJECT_SAMPLE_FACTORS           	PT14_biob_UCD2	CRS_26	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT15_biob_UCD2	CRS_27	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT02_biob_UCD4	CRS_28	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT01_ideal_UCD2	CRS_29	Treatment:Ideal	
SUBJECT_SAMPLE_FACTORS           	PT01_biob_UCD2	CRS_30	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT19_ideal_UCD2	CRS_31	Treatment:Ideal	
SUBJECT_SAMPLE_FACTORS           	PT19_biob_UCD4	CRS_32	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT06_biob_UCD2	CRS_33	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT04_ideal_UCD2	CRS_34	Treatment:Ideal	
SUBJECT_SAMPLE_FACTORS           	PT06_biob_UCD4	CRS_35	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT16_biob_UCD2	CRS_36	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT11_ideal_UCD2	CRS_37	Treatment:Ideal	
SUBJECT_SAMPLE_FACTORS           	PT16_biob_UCD4	CRS_38	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT05_biob_UCD2	CRS_39	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT10_biob_UCD4	CRS_40	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT09_ideal_UCD2	CRS_41	Treatment:Ideal	
SUBJECT_SAMPLE_FACTORS           	PT03_biob_UCD2	CRS_42	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT15_ideal_UCD2	CRS_43	Treatment:Ideal	
SUBJECT_SAMPLE_FACTORS           	PT08_ideal_UCD2	CRS_44	Treatment:Ideal	
SUBJECT_SAMPLE_FACTORS           	PT04_biob_UCD4	CRS_45	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT09_biob_UCD4	CRS_46	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT13_biob_UCD4	CRS_47	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT05_biob_UCD4	CRS_48	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT12_ideal_UCD2	CRS_49	Treatment:Ideal	
SUBJECT_SAMPLE_FACTORS           	PT03_ideal_UCD2	CRS_50	Treatment:Ideal	
SUBJECT_SAMPLE_FACTORS           	PT17_ideal_UCD2	CRS_51	Treatment:Ideal	
SUBJECT_SAMPLE_FACTORS           	PT05_ideal_UCD2	CRS_52	Treatment:Ideal	
SUBJECT_SAMPLE_FACTORS           	PT07_biob_UCD2	CRS_53	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT18_biob_UCD2	CRS_54	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT02_biob_UCD2	CRS_55	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT14_ideal_UCD2	CRS_56	Treatment:Ideal	
SUBJECT_SAMPLE_FACTORS           	PT14_biob_UCD4	CRS_57	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT10_ideal_UCD2	CRS_58	Treatment:Ideal	
SUBJECT_SAMPLE_FACTORS           	PT07_biob_UCD4	CRS_59	Treatment:Biob	
SUBJECT_SAMPLE_FACTORS           	PT13_biob_UCD2	CRS_60	Treatment:Biob	
#COLLECTION
CO:COLLECTION_SUMMARY            	Ideal: serum was collected and centrifuged within 30 min before being was
CO:COLLECTION_SUMMARY            	aliquoted into tubes and immediately frozen at -70 °C Biobank: serum was
CO:COLLECTION_SUMMARY            	collected and centrifuged within 30 min before sitting at room temperature 3
CO:COLLECTION_SUMMARY            	days, then placed in refrigerator 3 days, before being frozen at -70 °C
CO:COLLECTION_SUMMARY            	Biobank-FT: serum was collected and centrifuged within 30 min before sitting at
CO:COLLECTION_SUMMARY            	room temperature 3 days, then placed in refrigerator 3 days, before being frozen
CO:COLLECTION_SUMMARY            	at -70 °C, then thawed at room temperature for 30 minutes, then re-frozen at
CO:COLLECTION_SUMMARY            	-70 °C
CO:COLLECTION_PROTOCOL_FILENAME  	CHRI_Study_-_Prelim_Report_All_Data.docx
CO:SAMPLE_TYPE                   	Blood
CO:BLOOD_SERUM_OR_PLASMA         	Serum
#TREATMENT
TR:TREATMENT_SUMMARY             	Ideal: serum was collected and centrifuged within 30 min before being was
TR:TREATMENT_SUMMARY             	aliquoted into tubes and immediately frozen at -70 °C Biobank: serum was
TR:TREATMENT_SUMMARY             	collected and centrifuged within 30 min before sitting at room temperature 3
TR:TREATMENT_SUMMARY             	days, then placed in refrigerator 3 days, before being frozen at -70 °C
TR:TREATMENT_SUMMARY             	Biobank-FT: serum was collected and centrifuged within 30 min before sitting at
TR:TREATMENT_SUMMARY             	room temperature 3 days, then placed in refrigerator 3 days, before being frozen
TR:TREATMENT_SUMMARY             	at -70 °C, then thawed at room temperature for 30 minutes, then re-frozen at
TR:TREATMENT_SUMMARY             	-70 °C
TR:TREATMENT_PROTOCOL_FILENAME   	CHRI_Study_-_Prelim_Report_All_Data.docx
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	Non-esterified oxylipins, endocannabinoids, polyunsaturated fatty acids and bile
SP:SAMPLEPREP_SUMMARY            	acids extraction: Oxylipins, endocannabinoids, fatty acids and bile acids were
SP:SAMPLEPREP_SUMMARY            	isolated by liquid extraction protocol using methanol/acetonitrile mixture (1:1
SP:SAMPLEPREP_SUMMARY            	v/v] from 40 µL of serum and quantified by UPLC-MS/MS using internal standard
SP:SAMPLEPREP_SUMMARY            	methods. Procedure shortly: 40 µL of serum was mixed with 5 µL BHT/EDTA (1:1
SP:SAMPLEPREP_SUMMARY            	MeOH:water), 10 µL of 0.5 µM deuterated oxylipins and endocannabinoids
SP:SAMPLEPREP_SUMMARY            	surrogates and 20 µL of 1 µM deuterated bile acids surrogates in methanol.
SP:SAMPLEPREP_SUMMARY            	Next, serum was homogenized by addition of 200 µL of 1-cyclohexyl ureido,
SP:SAMPLEPREP_SUMMARY            	3-dodecanoic acid (CUDA) and 1-phenyl ureido 3-hexanoic acid (PUHA) at 100 nM in
SP:SAMPLEPREP_SUMMARY            	1:1 methanol:acetonitrile. Next, homogenate was centrifuge at 15000 rcf for 10
SP:SAMPLEPREP_SUMMARY            	min and the methanol/acetonitrile supernatant was collected for mass
SP:SAMPLEPREP_SUMMARY            	spectrometry analysis.
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_TYPE        	Reversed phase
CH:INSTRUMENT_NAME            	Waters Acquity UPLC
CH:COLUMN_NAME                	Waters 2.1 x 150mm, 1.7µm BEH C18 column
#ANALYSIS
AN:ANALYSIS_TYPE            	MS
#MS
MS:INSTRUMENT_NAME          	Waters Acquity UPLC
MS:INSTRUMENT_TYPE          	QTRAP
MS:MS_TYPE                  	ESI
MS:ION_MODE                 	NEGATIVE
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS	Concentration pmol/g
MS_METABOLITE_DATA_START
Samples	CRS_29	CRS_10	CRS_50	CRS_34	CRS_52	CRS_25	CRS_16	CRS_44	CRS_41	CRS_58	CRS_37	CRS_49	CRS_18	CRS_56	CRS_43	CRS_06	CRS_51	CRS_15	CRS_31	CRS_22	CRS_30	CRS_55	CRS_42	CRS_21	CRS_39	CRS_33	CRS_53	CRS_07	CRS_04	CRS_11	CRS_17	CRS_08	CRS_60	CRS_26	CRS_27	CRS_36	CRS_24	CRS_54	CRS_13	CRS_19	CRS_23	CRS_28	CRS_14	CRS_45	CRS_48	CRS_35	CRS_59	CRS_02	CRS_46	CRS_40	CRS_05	CRS_09	CRS_47	CRS_57	CRS_12	CRS_38	CRS_20	CRS_01	CRS_32	CRS_03
Factors	Treatment:Ideal	Treatment:Ideal	Treatment:Ideal	Treatment:Ideal	Treatment:Ideal	Treatment:Ideal	Treatment:Ideal	Treatment:Ideal	Treatment:Ideal	Treatment:Ideal	Treatment:Ideal	Treatment:Ideal	Treatment:Ideal	Treatment:Ideal	Treatment:Ideal	Treatment:Ideal	Treatment:Ideal	Treatment:Ideal	Treatment:Ideal	Treatment:Ideal	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob	Treatment:Biob
PGE2	0.184	0.224	0.137	0.171	0.0497	0.22	0.375	0.153	0.119	0.156	0.153	0.196	0.365	0.0644	0.149	0.303	0.124	0.678	0.284	0.452	0.172	0.125	0.114	0.285	0.161	0.318	0.0529	0.224	0.374	0.476	0.3	0.223	0.126	0.304	0.235	0.113	0.532	0.0871	0.159	0.29	0.204	0.188	0.189	0.135	0.0585	0.315	0.053	0.109	0.105	0.145	0.229	0.222	0.195	0.0895	0.125	0.0593	0.445	0.0728	0.258	0.203
PGD2	0.0997	0.108	0.00479	0.00674	0.0696	0.0201	0.011	0.0749	< LOD	0.111	0.0318	0.0427	0.0714	0.00136	0.0337	0.0518	0.0021	0.0544	0.0207	0.0431	0.133	0.106	0.0137	0.0833	0.197	0.137	0.0472	0.108	0.217	0.04	0.0475	0.04	0.0128	0.0238	0.00456	0.025	0.281	0.00396	0.047	0.066	0.0562	0.216	0.123	< LOD	0.0611	0.171	0.00242	0.203	0.0258	0.126	0.14	0.0034	0.0544	0.00357	0.0837	< LOD	0.327	0.114	0.0243	0.171
PGF2a Isoprostanes	0.34	0.404	< LOD	0.633	0.127	0.0476	< LOD	0.301	0.489	< LOD	0.144	0.0375	0.209	< LOD	0.0801	0.154	< LOD	0.271	0.144	0.00429	0.385	0.611	< LOD	0.521	0.293	0.175	< LOD	0.169	0.479	0.00324	0.0594	0.115	0.175	0.0429	0.0438	0.33	< LOD	0.304	0.133	0.0587	0.371	0.654	< LOD	0.313	0.117	0.115	< LOD	0.295	0.351	0.0902	0.0556	0.0318	0.203	0.0128	0.0958	0.391	< LOD	0.376	0.33	0.0336
TXB2	10.4	8.91	24	10.4	10.8	13.1	14.8	16.6	9.16	19.7	11.6	22.6	23.9	11	17.4	18.9	13.9	37.2	19	26	5.19	3.4	22.3	8.23	11.9	12.4	11.4	12.7	4.99	19.8	9.25	13.2	21.6	9.71	10.5	13.4	6.87	31.1	15.5	22.9	4.71	3.25	20	7.89	10.8	13.4	11.5	14.5	6.72	20.3	11	14.5	24.4	12	12.1	14.9	6.91	36.6	17.9	21.8
LTB4	0.142	0.147	0.989	0.0488	0.285	0.49	0.033	0.215	0.127	0.00861	0.00697	0.628	0.906	< LOD	0.117	0.0586	0.0836	0.382	0.193	0.088	0.186	0.0869	0.983	0.0638	0.302	0.515	0.0808	0.164	0.154	0.0285	0.0257	0.58	0.58	0.0145	0.101	0.0464	0.134	0.547	0.245	0.0459	0.136	0.106	1.02	0.0659	0.34	0.681	0.0306	0.205	0.12	0.0259	< LOD	0.519	1.03	0.0303	0.153	0.0791	0.141	0.566	0.319	0.0889
9,12,13-TriHOME	0.626	1.3	1.11	1.86	1.12	1.35	4.02	3.16	1.98	2.8	1.44	6.11	2.44	1.19	0.687	1.36	0.555	1.25	1.3	2.27	0.635	0.847	1.25	1.76	1.18	1.61	3.71	3.46	2.2	3.46	1.27	5.88	2.27	1.64	0.752	1.08	0.601	0.936	1.43	2.32	0.591	1.03	1.15	1.67	1.17	1.53	3.84	3.76	2.05	3.09	1.42	6.21	2.53	1.39	1.03	1.54	0.564	1.36	1.61	2.31
9,10-e-DiHO	1.19	1.13	1.14	1.95	0.526	3.56	2.42	1.8	1.59	1.95	1.44	0.964	13.8	1.48	1.28	1.26	1.45	1.73	2.08	2.76	1.1	1.29	1.37	2.52	1.07	4.42	2.81	1.56	1.37	2.85	1.45	1.22	16.3	2.37	1.09	1.49	1.14	1.83	1.69	2.32	1.07	1.72	1.18	1.99	1.18	5.27	2.15	1.52	1.79	3.13	1.57	1.73	20.9	1.92	1.28	1.79	2.24	0.127	2.08	3.03
9,10-DiHOME	1.82	2.28	1.01	5.88	2.17	3.74	3.74	5.83	1.92	13.6	1.4	9.41	10.3	2.51	1.06	2.62	1.17	2.77	2.35	2.16	2.2	2.26	1.26	6.21	2.76	5.18	4.28	4.69	2.23	18.4	1.54	9.12	12.1	4.85	1.12	2.95	1.16	2.89	2.18	2.55	1.9	2.7	1.17	5.55	2.61	5.59	4.33	5.24	2.34	19.1	1.66	8.33	13.9	4.4	1.39	3.49	1.22	3.7	2.84	2.28
15,16-DiHODE	2.35	5.38	1.5	7.66	13.2	19.8	13	19	6.58	14.4	3.37	7.65	6.93	14.9	3.38	15.2	2.19	7.66	7.71	5.49	2.76	5.25	1.58	8.12	14.8	24.2	14.3	19.1	6.67	20	2.63	7.45	5.71	20.4	2.61	13.8	2.29	8.2	6.96	5.87	2.1	4.86	1.65	6.8	14.2	26.7	14.8	21.9	5.97	20.3	3.58	6.85	7.61	19.5	4.05	16.4	2.42	10.6	8.67	5.76
9,10-DiHODE	0.0349	0.288	0.0777	0.792	0.13	0.504	0.281	0.611	0.156	0.549	0.0803	0.417	0.462	0.349	0.0572	0.311	0.037	0.166	0.141	0.127	0.0588	0.26	0.0785	0.882	0.127	0.717	0.33	0.562	0.248	0.832	0.0924	0.368	0.515	0.632	0.0865	0.305	0.0492	0.173	0.187	0.106	0.0609	0.253	0.0697	0.78	0.108	0.746	0.312	0.663	0.218	0.927	0.103	0.378	0.583	0.636	0.117	0.399	0.0411	0.263	0.219	0.116
14,15-DiHETrE	0.151	0.166	0.327	0.195	0.232	0.114	0.143	0.222	0.194	0.194	0.137	0.265	0.261	0.212	0.197	0.246	0.151	0.438	0.224	0.164	0.17	0.166	0.424	0.254	0.278	0.188	0.143	0.246	0.226	0.304	0.156	0.245	0.291	0.258	0.153	0.293	0.154	0.437	0.208	0.16	0.175	0.227	0.413	0.206	0.261	0.185	0.175	0.269	0.217	0.311	0.184	0.26	0.421	0.255	0.219	0.324	0.179	0.552	0.257	0.192
11,12-DiHETrE	0.151	0.138	0.243	0.188	0.148	0.098	0.0946	0.188	0.067	0.142	0.0953	0.226	0.255	0.161	0.148	0.252	0.122	0.393	0.134	0.0953	0.218	0.117	0.355	0.361	0.421	0.264	0.136	0.327	0.25	0.422	0.253	0.273	0.51	0.411	0.19	0.279	0.211	0.402	0.222	0.181	0.176	0.152	0.367	0.263	0.397	0.278	0.15	0.358	0.244	0.396	0.287	0.297	0.586	0.382	0.211	0.347	0.171	0.556	0.295	0.194
8,9-DiHETrE	0.028	0.0253	0.0762	0.0588	0.0759	0.0574	< LOD	0.0668	0.0336	< LOD	0.0205	0.131	0.059	0.00478	< LOD	0.0793	0.0299	0.15	0.0538	0.0806	0.252	0.258	0.471	1.26	1.15	0.913	0.195	0.936	1.14	0.861	0.742	0.587	1.42	0.915	0.278	0.238	0.247	0.536	0.759	0.388	0.206	0.206	0.422	1.16	1.11	1.09	0.198	1.19	1.09	0.862	1.04	0.527	2.02	0.758	0.301	0.37	0.345	0.893	0.932	0.361
5,6-DiHETrE	0.0476	0.0836	0.0853	0.0968	0.0242	0.139	0.0527	0.057	0.0437	0.0468	0.0275	0.153	0.106	0.0219	0.0803	0.137	0.153	0.138	0.0677	0.0494	2.17	1.56	2.46	1.42	1.13	2.42	1.38	1.02	1.2	0.993	0.993	3.15	1.44	1.1	1.77	2.83	4.51	2.77	0.858	1.89	1.91	1.7	2.44	1.21	1.02	2.65	1.57	1.22	1.1	1	1.17	3.22	1.83	1	2.28	3.27	4.48	3.85	1.07	1.91
17,18-DiHETE	1.04	4.78	1.11	1.84	1.01	0.576	0.901	1.75	1.2	1.02	0.707	1.45	2.27	0.164	0.466	3.78	0.635	2.41	1.57	0.731	1.78	3.88	1.26	1.68	1.71	0.988	0.789	1.78	1.2	0.968	0.517	1.11	1.29	1.29	0.482	3.31	0.925	1.62	0.819	1.08	1.15	5.37	0.918	1.8	1.31	1.29	0.754	2.47	1.16	1.2	1.96	1.49	1.48	0.55	1.09	3.4	1.04	3.12	1.11	0.992
19,20-DiHDoPE	0.503	1.35	0.621	1.18	0.925	0.363	0.272	0.544	0.577	0.351	0.429	0.708	0.969	0.162	0.229	1.74	0.404	1.04	0.514	0.498	0.535	1.2	0.835	1.11	1.21	0.571	0.213	0.577	0.606	0.573	0.412	0.769	1.01	0.351	0.204	1.75	0.339	0.971	0.502	0.546	0.463	1.45	0.874	0.986	1.01	0.562	0.254	0.576	0.552	0.605	0.527	0.73	1.24	0.307	0.29	2.29	0.36	1.26	0.582	0.535
13-HODE	3.51	5.32	5.59	3.94	3.35	11.1	7.59	9.39	10.2	26.3	4.6	11.4	4.88	5.99	5.55	5.86	2.67	18.4	5.25	2.11	5.45	8.77	8.39	7.09	7.31	22.1	17.4	8.79	11.3	32.2	7.1	17.2	12.4	13.9	6.57	8.23	8.95	16.4	7.71	5.4	4.91	12.9	8.35	7.51	6.1	22.7	16.6	9.65	11.4	30.1	8.69	16.9	13.6	9.61	6.51	9.49	8.44	21	9.13	6.07
9-HODE	2.3	3.29	3.68	2.51	2.03	4.99	8.05	7.05	6	22.5	2.91	8.3	8.8	3.93	4.58	5.56	2.99	14.2	4.18	1.32	3.05	6.79	5.17	4.7	4.51	11.3	20.8	5.66	10.2	24.5	4.5	15.5	16.8	9.13	5.22	5.32	8.22	10.9	5.3	3.26	2.94	7.68	5.16	4.7	4.06	10.9	21.5	6.29	10.4	23.9	5.79	15.9	17.6	7.6	4.48	6.09	7.77	15.8	6.57	4.11
13-HOTE	< LOD	0.0294	0.0257	1.04	1.11	4.67	0.552	1.18	1.17	7.04	0.0404	0.746	0.232	3.76	0.231	0.377	< LOD	1.22	0.498	< LOD	0.0437	0.218	0.0854	0.87	0.994	6.07	1.42	0.301	0.929	2.36	0.0125	1.03	0.889	6.15	0.0775	0.413	0.244	1.14	0.223	0.00643	< LOD	0.443	0.132	0.968	0.991	7.33	1.92	0.388	0.705	1.85	0.394	1.07	1.1	4.87	0.149	0.788	0.349	1.16	0.799	0.342
9-HOTE	0.171	0.197	0.23	0.244	0.177	0.645	0.66	0.628	0.419	0.745	0.161	0.626	0.935	0.85	0.239	0.237	0.272	0.739	0.25	0.0792	0.186	0.293	0.363	0.364	0.247	1.13	1.37	0.448	0.612	0.917	0.156	0.936	1.2	1.63	0.207	0.282	0.503	0.684	0.259	0.158	0.142	0.372	0.307	0.369	0.254	1.16	1.51	0.55	0.675	0.884	0.107	0.859	1.39	1.44	0.222	0.331	0.458	0.904	0.366	0.175
15-HETE	0.333	0.0479	1	0.234	0.416	0.354	0.558	0.722	0.45	1.46	0.345	0.736	0.746	0.423	0.909	0.742	0.371	2.01	0.909	1.03	0.683	1.16	2.03	1.25	1.19	2.69	1.35	0.978	1.4	1.3	1.31	1.76	3.23	1.03	1.58	1.44	2.34	2.45	1.58	1.86	0.831	1.32	2.06	1.17	0.954	2.59	1.61	1.39	1.07	1.29	1.47	1.87	2.52	1.18	1.61	1.95	2.27	3.48	1.69	2.03
12-HETE	10.6	2.22	54.3	8.96	14.9	11.3	29.3	12.7	40.3	13.2	7.59	33.9	42.9	6.85	33.2	32.1	14.1	69.8	34.2	48.6	14.7	3.99	75.6	12.5	19.9	17.6	32.2	15.3	55	28.1	13.1	37.9	38.5	12.9	31.6	32.8	19.1	73.7	37.1	56.3	11.9	4.9	77.5	10.5	17.8	20.4	32	17.2	52.2	26.5	15.8	38.9	51.1	11.1	44.1	40	18.3	107	43.7	59.7
11-HETE	0.112	0.0707	0.804	0.0792	0.0751	0.162	0.245	0.224	0.0738	0.828	0.289	0.456	0.743	0.161	0.469	0.595	0.457	1.48	0.563	0.867	0.21	0.9	1.79	0.907	0.968	3.15	0.462	0.873	1.02	1.62	1.79	0.939	2.43	0.587	0.834	0.858	2.39	1.75	1.5	1.64	0.327	1.04	1.83	0.956	0.718	2.95	0.582	0.945	1.03	1.46	2.35	0.886	2.52	1	1.05	1.05	1.85	2.68	1.64	1.96
5-HETE	0.663	0.541	2.99	0.266	0.718	1.75	0.249	0.946	0.539	0.336	0.284	2.27	1.98	0.187	0.637	0.802	0.578	2.52	0.72	0.558	4.84	33.6	32.4	6.65	5.03	14	8.12	4.75	5.48	3.59	6.91	19.4	6.94	3.11	12.8	16.4	91.7	19.1	3.66	17.8	4.95	46.2	42.6	5.8	4.08	13.8	6.88	6.31	5.05	3.13	10.5	21.4	7.98	2.85	17.6	18.8	89.2	36.9	4.9	29.3
12-HEPE	0.248	0.154	0.315	0.212	0.0982	0.078	0.221	0.126	0.319	0.13	0.103	0.281	0.367	0.039	0.242	0.654	0.142	0.859	0.354	0.373	0.478	0.96	0.567	0.411	0.232	0.282	0.38	0.283	0.768	0.286	0.41	0.397	0.438	0.132	0.328	1.23	0.383	1.23	0.541	0.538	0.472	1.16	0.526	0.352	0.15	0.279	0.364	0.24	0.532	0.31	0.494	0.307	0.658	0.159	0.484	1.38	0.362	1.67	0.593	0.527
9-HEPE	0.0776	0.126	0.0599	0.0738	0.0552	0.0626	0.0747	0.083	0.0701	0.0879	0.0578	0.0685	0.0891	0.0639	0.0666	0.0836	0.065	0.0908	0.087	0.0775	0.1	0.62	0.11	0.242	0.0952	0.18	0.129	0.125	0.172	0.133	0.133	0.0697	0.158	0.112	0.0911	0.152	0.22	0.11	0.257	0.106	0.0948	0.726	0.0812	0.123	0.0794	0.19	0.137	0.2	0.191	0.0733	0.183	0.0781	0.183	0.13	0.0925	0.263	0.171	0.146	0.251	0.132
5-HEPE	0.0667	0.204	0.0364	0.0525	< LOD	0.0231	< LOD	0.0434	0.00677	< LOD	0.00317	0.0426	0.0378	< LOD	< LOD	0.121	0.0242	0.0904	< LOD	0.0187	0.388	10.3	0.811	0.622	0.263	0.387	0.358	0.412	0.297	0.174	0.331	0.695	0.262	0.265	0.399	1.96	4.26	0.732	0.343	0.705	0.323	14.7	1.06	0.478	0.165	0.434	0.345	0.412	0.228	0.162	0.416	0.845	0.338	0.2	0.641	2.09	4.03	1.17	0.51	1.04
17-HDoHE	0.519	0.521	0.528	0.0504	< LOD	0.12	0.114	0.589	< LOD	0.864	0.265	0.0469	1.96	< LOD	0.296	< LOD	0.516	0.156	< LOD	0.783	0.521	1.69	6.55	1.08	0.682	1.31	0.0854	0.0986	0.0753	< LOD	0.0778	0.734	0.806	0.118	5.35	0.675	2.49	< LOD	4.26	0.335	0.156	2.13	0.744	4.5	3.33	1.94	0.0711	< LOD	0.231	0.502	1.45	0.756	0.819	0.283	< LOD	1.38	2.48	0.696	< LOD	0.471
12(13)-EpOME	0.523	1.3	0.84	1.02	0.324	3.69	2.75	1.08	4.04	3.86	0.959	1.97	4.66	0.853	0.0966	0.0706	0.0914	1.18	0.972	< LOD	0.968	1.03	2.1	1.15	0.772	6.29	5.46	1.54	5.03	6.61	1.79	3.35	4.38	2.25	0.189	0.287	0.221	1.3	1.09	0.241	1.04	1.56	1.81	1.26	0.934	6.36	4.02	1.44	4.01	6.3	2.37	3.48	8.66	1.88	0.417	0.406	0.407	2.01	1.48	0.292
15(16)-EpODE	< LOD	0.0274	< LOD	0.129	0.119	0.645	< LOD	0.284	0.0607	0.247	< LOD	< LOD	0.171	0.313	0.16	0.0857	< LOD	0.243	0.141	< LOD	< LOD	0.0387	0.0166	0.186	0.133	0.792	0.0398	0.235	0.0839	0.228	0.00323	0.105	0.295	0.958	0.0326	0.0884	0.0717	0.216	0.0827	< LOD	< LOD	0.0731	0.132	0.209	0.0645	0.792	0.13	0.104	0.0967	0.208	< LOD	0.159	0.304	0.484	0.0598	0.091	0.0296	0.219	0.0488	0.0334
9(10)-EpODE	< LOD	0.0274	< LOD	0.129	0.119	0.645	< LOD	0.284	0.0607	0.247	< LOD	< LOD	0.171	0.313	0.16	0.0857	< LOD	0.243	0.141	< LOD	< LOD	0.0387	0.0166	0.186	0.133	0.792	0.0398	0.235	0.0839	0.228	0.00323	0.105	0.295	0.958	0.0326	0.0884	0.0717	0.216	0.0827	< LOD	< LOD	0.0731	0.132	0.209	0.0645	0.792	0.13	0.104	0.0967	0.208	< LOD	0.159	0.304	0.484	0.0598	0.091	0.0296	0.219	0.0488	0.0334
13-KODE	7.61	6.76	18.1	9.6	12.1	13.6	9.89	27.1	24	75.2	15.5	5.68	7.66	18.6	28.2	19.9	9.93	37.6	8.21	0.807	2.27	13.2	9.08	5.55	8.51	8.89	15.4	3.71	6.8	9.59	4.54	6.37	18.6	5.97	13.4	10.1	9.24	10	4.92	5.32	2.77	14.1	7.18	9.84	5.93	11	19.5	7.82	3.99	9.56	4.89	7.57	10.4	8.07	5.63	6.85	6.06	12.5	5.18	6.14
9-KODE	0.598	0.923	0.104	0.833	0.167	0.629	0.806	0.548	1.41	4.98	0.609	0.766	1.18	1.04	0.222	1.16	0.466	0.551	0.451	0.359	0.441	1.46	0.753	1.45	0.556	2.27	3.38	0.835	1.8	5.04	0.779	1.68	3.01	4.01	0.81	0.268	0.948	0.768	1.06	0.709	0.505	2.52	0.33	1.59	0.462	1.49	2.74	1.41	1.43	4.64	0.817	1.84	2.85	3.37	0.767	0.818	0.399	1.52	1.34	1.29
5-KETE	0.0457	0.0134	0.223	0.0332	0.0814	0.0889	< LOD	0.236	0.305	0.354	0.0395	0.0976	0.136	< LOD	0.0991	0.0541	< LOD	0.249	0.0702	< LOD	0.00678	0.769	0.938	0.191	0.345	0.658	0.141	0.0612	0.167	0.155	0.479	0.371	0.254	< LOD	0.267	0.321	2.83	0.62	0.0537	0.245	0.123	2.05	1.17	0.0898	0.0167	0.745	0.175	0.105	0.0118	0.109	0.932	0.347	0.147	0.0419	0.408	0.675	2.2	1.06	0.096	0.687
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	HMDB ID	InChIKey	PubChem CID	KEGG
PGE2	HMDB01220	XEYBRNLFEZDVAW-ARSRFYASSA-N	5280360	C00584
PGD2	HMDB01403	BHMBVRSPMRCCGG-OUTUXVNYSA-N	448457	C00696
PGF2a Isoprostanes
TXB2	HMDB03252	XNRNNGPBEPRNAR-JQBLCGNGSA-N	5283137
LTB4	HMDB02886	KFGOFTHODYBSGM-ZUNNJUQCSA-N	5280888	C05961
9,12,13-TriHOME	HMDB04708	MDIUMSLCYIJBQC-MVFSOIOZSA-N	9858729	C14833
9,10-e-DiHO		VACHUYIREGFMSP-SJORKVTESA-N	441460
9,10-DiHOME	HMDB04704	XEBKSQSGNGRGDW-YFHOEESVSA-N	9966640	C14828
15,16-DiHODE	HMDB10208	LKLLJYJTYPVCID-OHPMOLHNSA-N	16061068
9,10-DiHODE	HMDB10221	QRHSEDZBZMZPOA-ZJSQCTGTSA-N	16061066
14,15-DiHETrE	HMDB02265	SYAWGTIVOGUZMM-ILYOTBPNSA-N	5283147	C14775
11,12-DiHETrE	HMDB02314	LRPPQRCHCPFBPE-KROJNAHFSA-N	5283146	C14774
8,9-DiHETrE	HMDB02311	DCJBINATHQHPKO-TYAUOURKSA-N	5283144	C14773
5,6-DiHETrE	HMDB02343	GFNYAPAJUNPMGH-QNEBEIHSSA-N	5283142	C14772
17,18-DiHETE	HMDB10211	XYDVGNAQQFWZEF-JPURVOHMSA-N	16061120
19,20-DiHDoPE	HMDB10214	FFXKPSNQCPNORO-MBYQGORISA-N	16061148
13-HODE	HMDB04667	HNICUWMFWZBIFP-IRQZEAMPSA-N	6443013	C14762
9-HODE	HMDB10223	NPDSHTNEKLQQIJ-SIGMCMEVSA-N	5282945
13-HOTE	HMDB10203	KLLGGGQNRTVBSU-JDTPQGGVSA-N	10469728
9-HOTE	HMDB10224	YUPHIKSLGBATJK-OBKPXJAFSA-N	53480359
15-HETE	HMDB03876	JSFATNQSLKRBCI-VAEKSGALSA-N	5280724	C04742
12-HETE	HMDB06111	ZNHVWPKMFKADKW-FYMOKONMSA-N	5312983
11-HETE	HMDB04682	GCZRCCHPLVMMJE-RSPKXIRXSA-N	5312981
5-HETE	HMDB11134	KGIJOOYOSFUGPC-JGKLHWIESA-N	5280733	C04805
12-HEPE	HMDB10202	MCRJLMXYVFDXLS-QGQBRVLBSA-N	10041593
9-HEPE		OXOPDAZWPWFJEW-FPRWAWDYSA-N	5283187
5-HEPE	HMDB05081	FTAGQROYQYQRHF-FCWZHQICSA-N	6439678
17-HDoHE	HMDB10213	SWTYBBUBEPPYCX-VIIQGJSXSA-N	6439179
12(13)-EpOME	HMDB04702	CCPPLLJZDQAOHD-FLIBITNWSA-N	5356421
15(16)-EpODE	HMDB10206	HKSDVVJONLXYKL-OHPMOLHNSA-N	16061062
9(10)-EpODE	HMDB10220	JTEGNNHWOIJBJZ-ZJSQCTGTSA-N	16061060
13-KODE	HMDB04668	JHXAZBBVQSRKJR-BSZOFBHHSA-N	6446027	C14765
9-KODE	HMDB04669	LUZSWWYKKLTDHU-ZJHFMPGASA-N	9839084	C14766
5-KETE	HMDB10217	MEASLHGILYBXFO-XTDASVJISA-N	5283159	C14732
METABOLITES_END
#FACTORS
#END
